Recent insider trends for Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) have caught the attention of investors. Analysts monitor insider data to understand the sentiment of a company’s largest and most important shareholders. INFI’s insider trading patterns have some implications for where the stock might be headed.
Institutions own 67.51% of Infinity Pharmaceuticals, Inc. (INFI)’s shares. The total value of these holdings, in millions, is $57. Among active positions in the latest quarter, 32 holders increased their positions by a total of 3.65 million shares, 48 holders decreased the positions by a total of 8.01 million shares, and 15 holders held their positions. This works out to a net decrease in ownership of 4.35 million shares, and suggests that institutions are feeling bearish about the stock.
Among new and sold out positions, 17 holders initiated new positions by a total of 2.02 million shares and 23 holders exited their positions by a total of 3.24 million shares. This nets out to a decrease of 1.22 million shares and is another bearish sign for INFI.
In the last three months, insiders executed a total of 5 trades. 5 of these were buys. Insider ownership increased by a total of 1.73 million shares, which suggests that INFI’s key executives are feeling more optimistic about the outlook for the stock. The data from the past twelve months tells a similar story: insiders executed 21 buys and 3 sells, and ownership increased by a net of 3.56 million shares.
Short interest, or the number of a stock’s tradable shares currently being shorted, is another metric investors use to get a pulse on sentiment. Infinity Pharmaceuticals, Inc. (NASDAQ:INFI)’s short interest is 817000 shares, or 2.07% of the float. This represents an increase of 12% in the number of shares being shorted compared to the previous reading, and implies that investors felt more pessimistic about the stock during the past two weeks.
In light of the insider ownership and trading data it makes sense to consider technicals to see if they come to a similar conclusion about the outlook for INFI. A composite of 13 technical indicators that includes measures such as moving averages and momentum oscillators suggests that INFI is a Strong buy, which implies that INFI is expected to outperform the market based on prior trading patterns.
Institutional ownership trends suggest that the stock is cheap and the insider trading data indicates that insiders are bullish. Technical indicators (also) suggest that Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) is undervalued.